NANTES, FRANCE--(MARKET WIRE)--Aug 14, 2007 --
VIVALIS (Euronext Paris : VLS), a biopharmaceutical company specialised in development and marketing of technologies dedicated to the production of vaccines and production of antiviral diseases products, announces its revenues for the first quarter 2007 and the 1st semester 2007, closing June 30th 2007.
